Company: INCR
Filing Date: 2025-05-01
Form Type: 20-F
Source: 0001641172-25-007971
Chunk: 0

Company: Intercure Ltd.
Filing Date: 2025-05-01
Form: 20-F
Item: Item 3
Chunk 0
---

ITEM       KEY    
 3.    INFORMATION
------------------

A.   Reserved.
--------------

B.     Capitalization 
     and Indebtedness.
----------------------
 
Not applicable.
 

C.                Reasons              
     for the Offer and Use of Proceeds.
---------------------------------------
 
Not applicable.
 

8
-

D.     Risk  
     Factors.
-------------
 
Investing in our ordinary shares involves a high degree of risk. You should carefully consider the risks and uncertainties described below, in addition to the other information set forth in this Annual Report on Form 20-F, including the consolidated financial statements and the related notes included elsewhere in this Annual Report, before purchasing our ordinary shares. If any of the following risks actually occurs, our business, financial condition, cash flows and results of operations could be negatively impacted. In that case, the trading price of our ordinary shares would likely decline and you might lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.
 
Summary Risk Factors
 
Investing in our ordinary shares involves a high degree of risk, as fully described below. The principal factors and uncertainties that make investing in our ordinary shares risky, include, but are not limited to:

●                                                                     The                                                                  
                                medical-use cannabis industry in Israel and other countries is highly regulated;                           
-------------------------------------------------------------------------------------------------------------------------------------------
●   We                                                                                                                                     
    are dependent upon regulatory approvals and licenses for our ability to produce and distribute our pharmaceutical-grade cannabis       
    products;                                                                                                                              
●   Research                                                                                                                               
    on the effects of cannabis has been limited.                                                                                           
●   We                                                                                                                                     
    compete for market share with companies that may have longer operating histories, more financial resources, and greater manufacturing  
    and marketing experience than us.                                                                                                      
●   Potential                                                                                                                              
    anti-dumping and tariff duties on imports from Canada could increase costs and affect our business.                                    
●   Legal                                                                                                                                  
    and illegal use of cannabis for non-medical purposes may have a significant negative effect on the medical-use cannabis industry       
    and our pharmaceutical-grade cannabis business.                                                                                        
●   Our                                                                                                                                    
    business is subject to, or may become subject to, a variety of U.S. and foreign laws relating to the production and distribution       
    of cannabis, many of which are unsettled and still developing, and which could subject us to claims or otherwise harm our business.    
●   We                                                                                                                                     
    are subject to risks inherent in an agricultural business, which include the